U.S. markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,850.60
    +3.00 (+0.16%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.01%)
     
  • BTC-USD

    29,158.33
    +271.52 (+0.94%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.

  • Chronic HDV infection is the most severe form of viral hepatitis.

  • Bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.

  • In Europe, Hepcludex (bulevirtide) has been granted Conditional Marketing Authorization and PRIority MEdicines (PRIME) status for chronic HDV infection with compensated liver disease.

  • Interim results from the Phase 3 MYR301 study indicate that after 24 weeks of therapy, 36.7% of bulevirtide patients achieved the combined virological and biochemical response.

  • Treatment for 24 weeks with bulevirtide 2 mg had a statistically significant response compared to the no-treatment group.

  • Additionally, rapid alanine aminotransferase (liver enzymes) reduction and normalization were observed in over 50% of people with HDV in the bulevirtide 2 mg group compared with the no treatment group (5.9%).

  • Price Action: GILD shares are up 0.89% at $68.39 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.